STOCK TITAN

Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference

Lilly (NYSE: LLY) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 28, 2026.

(Neutral)
(Neutral)
Tags

Lilly (NYSE: LLY) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 28, 2026. Daniel M. Skovronsky, chief scientific and product officer and president of Lilly Research Laboratories, will join a fireside chat at 1:30 p.m. Eastern time.

A live audio webcast and a 90-day replay will be available on Lilly's investor website under "Webcasts & Presentations".

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.
Argus May 18 session
-1.67% close to close Open Argus
Details

News Market Reaction – LLY

On May 18, the day this news came out, LLY closed 1.67% below the previous close.

Data tracked by StockTitan Argus for the May 18 session.

Market Context

This announcement highlights LLY’s plan to engage investors at a major conference via a fireside cha...
Analysis

This announcement highlights LLY’s plan to engage investors at a major conference via a fireside chat on May 28, 2026, with a webcast and 90-day replay. It follows a series of strong earnings, clinical, and strategic updates in recent weeks, reinforcing ongoing investor outreach rather than introducing new financial metrics. Observers may focus on how management frames growth, R&D priorities, and capital allocation in light of recent results and large-scale investments.

Key Figures

Conference edition: 42nd annual Conference date: May 28, 2026 Fireside chat time: 1:30 p.m. ET +1 more
Conference edition
42nd annual
Bernstein Strategic Decisions Conference
Conference date
May 28, 2026
Bernstein Strategic Decisions Conference appearance
Fireside chat time
1:30 p.m. ET
Scheduled Lilly session at conference
Webcast replay window
90 days
Replay availability on investor website

Historical Context

5 past events · Latest: May 14
5 events
  1. May 14

    UNICEF collaboration

    24h Move
    -0.9%

    Six-year $50M UNICEF NCD initiative for 30M children and caregivers.

  2. May 12

    Obesity trial data

    24h Move
    +2.6%

    Late-phase data on Foundayo and Zepbound maintaining weight loss after switch.

  3. May 12

    Community initiative

    24h Move
    +2.4%

    150th anniversary program supporting 500,000 meals and 150 food pantries.

  4. May 6

    Capex expansion

    24h Move
    -0.2%

    $4.5B Indiana investment and opening of genetic medicine facility.

  5. May 5

    Clinical durability data

    24h Move
    +2.2%

    Omvoh four-year disease clearance durability in ulcerative colitis.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

INDIANAPOLIS, May 18, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 28, 2026. Daniel M. Skovronsky, M.D., Ph.D., chief scientific and product officer, and president of Lilly Research Laboratories, will take part in a fireside chat at 1:30 p.m., Eastern time.

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Refer to:

Ashley Hennessey; gentry_ashley_jo@lilly.com; 317-416-4363 (Media)


Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors)

Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-to-participate-in-bernsteins-42nd-annual-strategic-decisions-conference-302774752.html

SOURCE Eli Lilly and Company

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Lilly (LLY) present at Bernstein's 42nd Annual Strategic Decisions Conference in 2026?

Lilly will present at Bernstein's 42nd Annual Strategic Decisions Conference on May 28, 2026. According to Lilly, a fireside chat featuring Daniel M. Skovronsky is scheduled for 1:30 p.m. Eastern time, with a live audio webcast for investors.

Who will represent Lilly (LLY) at Bernstein's 42nd Annual Strategic Decisions Conference 2026?

Daniel M. Skovronsky will represent Lilly at the Bernstein 2026 conference. According to Lilly, he serves as chief scientific and product officer and president of Lilly Research Laboratories and will participate in a fireside chat for investors.

How can investors listen to Lilly's (LLY) fireside chat at Bernstein's 2026 conference?

Investors can listen via a live audio webcast on Lilly's investor website. According to Lilly, the session will be in the "Webcasts & Presentations" section, with access provided at the scheduled time of the fireside chat.

Will a replay of Lilly's (LLY) Bernstein 2026 conference presentation be available?

Yes, a replay of Lilly's Bernstein 2026 fireside chat will be available. According to Lilly, the replay will remain accessible on the same "Webcasts & Presentations" page of the investor website for approximately 90 days after the event.

What time is Lilly's (LLY) fireside chat at Bernstein's 42nd Annual Strategic Decisions Conference?

Lilly's fireside chat is scheduled for 1:30 p.m. Eastern time on May 28, 2026. According to Lilly, Daniel M. Skovronsky will participate, and investors can access a simultaneous live audio webcast online.

Keep reading